Concerns About Eye Toxicity Could Limit GSK’s Myeloma Drug Potential
US FDA Flags Safety Ahead Of Meeting
Company told more measures needed to limit damage to patients' eyes caused by antibody drug conjugate.
You may also be interested in...
The antibody-drug conjugate now looks set for US approval, but its limitations leave plenty of scope for CAR-T and bispecific rivals.
A new outlicensing deal with Viatris will keep it afloat for now but Idorsia needs more time, money and R&D success to secure its long-term future.
The gene therapy company could have two products approved by the end of 2024 – with ambitions for long-term expansion beyond rare disease.